DE3780770T2 - Therapeutisches gemisch aus einem faenger von freien radikalen oder einem stoffwechsel-hemmer und einem biologisch aktiven protein. - Google Patents

Therapeutisches gemisch aus einem faenger von freien radikalen oder einem stoffwechsel-hemmer und einem biologisch aktiven protein.

Info

Publication number
DE3780770T2
DE3780770T2 DE8787117149T DE3780770T DE3780770T2 DE 3780770 T2 DE3780770 T2 DE 3780770T2 DE 8787117149 T DE8787117149 T DE 8787117149T DE 3780770 T DE3780770 T DE 3780770T DE 3780770 T2 DE3780770 T2 DE 3780770T2
Authority
DE
Germany
Prior art keywords
tnf
lymphokine
cytotoxin
biological
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8787117149T
Other languages
German (de)
English (en)
Other versions
DE3780770D1 (de
Inventor
Marafino, Jr
Robert Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Cetus Oncology Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Oncology Corp filed Critical Cetus Oncology Corp
Publication of DE3780770D1 publication Critical patent/DE3780770D1/de
Application granted granted Critical
Publication of DE3780770T2 publication Critical patent/DE3780770T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE8787117149T 1986-11-21 1987-11-20 Therapeutisches gemisch aus einem faenger von freien radikalen oder einem stoffwechsel-hemmer und einem biologisch aktiven protein. Expired - Fee Related DE3780770T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93347586A 1986-11-21 1986-11-21
US11364387A 1987-10-26 1987-10-26

Publications (2)

Publication Number Publication Date
DE3780770D1 DE3780770D1 (de) 1992-09-03
DE3780770T2 true DE3780770T2 (de) 1993-02-25

Family

ID=26811304

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787117149T Expired - Fee Related DE3780770T2 (de) 1986-11-21 1987-11-20 Therapeutisches gemisch aus einem faenger von freien radikalen oder einem stoffwechsel-hemmer und einem biologisch aktiven protein.

Country Status (5)

Country Link
EP (1) EP0269017B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1321349C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3780770T2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2042529T4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR3005314T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5296500A (en) * 1991-08-30 1994-03-22 The Procter & Gamble Company Use of N-acetyl-cysteine and derivatives for regulating skin wrinkles and/or skin atrophy
US5523077A (en) * 1992-02-06 1996-06-04 Yale University Composition and method for whitening skin
GB9226729D0 (en) * 1992-12-22 1993-02-17 Wellcome Found Therapeutic combination
DE69330285D1 (de) * 1993-03-10 2001-07-05 Univ Yale New Haven Mittel und verfahren zur bleichung der haut
US5686436A (en) 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
WO1995024894A2 (en) * 1994-03-14 1995-09-21 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
US5451405A (en) * 1994-04-25 1995-09-19 Chesebrough-Pond's Usa Co. Skin treatment composition
EP1107784A2 (en) * 1998-08-24 2001-06-20 Maxim Pharmaceuticals, Inc. Activation and protection of t-cells (cd4?+ and cd8?+ ) using an h 2? receptor agonist and other t-cell activating agents
CA3075035A1 (en) 2017-09-07 2019-03-14 The Children's Hospital Of Philadelphia Compositions and methods for treatment of hereditary cystatin c amyloid angiopathy (hccaa) and other neurodegenerative disorders associated with aberrant amyloid deposits

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1526205A (en) * 1974-11-07 1978-09-27 Searle & Co Treatment of interferon-like material
EP0177342A3 (en) * 1984-10-04 1987-12-02 Genentech, Inc. Oral formulation of therapeutic proteins

Also Published As

Publication number Publication date
EP0269017A3 (en) 1989-06-21
JPS63190831A (ja) 1988-08-08
GR3005314T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-05-24
DE3780770D1 (de) 1992-09-03
ES2042529T3 (es) 1993-12-16
EP0269017B1 (en) 1992-07-29
CA1321349C (en) 1993-08-17
ES2042529T4 (es) 1996-07-16
EP0269017A2 (en) 1988-06-01

Similar Documents

Publication Publication Date Title
US5702697A (en) Treatment for biological damage using a colony stimulating factor and a biological modifier
US4985241A (en) Therapeutic combination of free-radical scavenger and tumor necrosis factor
DE69632062T2 (de) Kontinuierliche, niedrigdosierte zytokine-infusionstherapie
DE69333321T3 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
DE69330032T2 (de) Therapeutisches kombinationspräparat enthaltend interferon
DE69927971T2 (de) Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
DE69735202T2 (de) Stimulierung wirtseigener abwehrmechanismen gegen krebs
DE69820247T2 (de) Polyethylene glycol-interferon alpha konjugate für therapie der infektionen
DE3876125T2 (de) Behandlung der menschlichen viralinfektion durch doppelstrang-rna, kombiniert mit viralen inhibitoren.
DE69732225T2 (de) Verfahren zur Verkapselung von biologisch aktiven Stoffen in Erythrocyten und Gerät dafür
DE69328558T2 (de) Pharmazeutisches Präparat zur synergistischen Aktivierung natürlicher Killerzellen
DE69434121T2 (de) Pharmazeutische zusammensetzung zur immunverstärkenden therapie
DE69026620T2 (de) Anti-tumor-zubereitung enthaltend interleukin-2 und histamin, analoge dazu oder h2-rezeptor-agonisten
JPH02304027A (ja) 前新生物性病変の全身的治療のための少なくとも１種のサイトカインを含む製剤組成物の使用
DD241271A5 (de) Verfahren zur unterscheidung von normalen und boesartigen zellen in einer mischung in vitro
DE69634074T2 (de) Thiole zur Förderung des Wachstums von Hömatopoietischen Vorläuferzellen
EP0107498A2 (en) Synergistic human interferon activity
DE3780770T2 (de) Therapeutisches gemisch aus einem faenger von freien radikalen oder einem stoffwechsel-hemmer und einem biologisch aktiven protein.
DE3854726T2 (de) Synergistische Wechselwirkung von Interleukin-2 und doppelsträngiger RNS.
CA1320446C (en) Modulation of lymphokine-resistant cellular states by dsrnas
DE69620233T2 (de) Oxidiertes glutathion als mittel zur verbesserung der endogenen produktion von cytokinen und haematopoietischen faktoren
DE69130679T2 (de) Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation
DE3856516T2 (de) Verwendung von rekombinantem koloniestimulierendem Faktor-1 zur Herstellung eines Medikaments gegen Cytomegalovirusinfektionen
DE69116321T2 (de) Immunostimulierendes Mittel das Interleukin-2 und 5'-Deoxy-5-fluorouridin enthält
DE3853898T2 (de) Behandlung der RNase L-Defizienz mit ds RNS.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CHIRON CORP. (N.D.GES.D. STAATES DELAWARE), EMERYV

8339 Ceased/non-payment of the annual fee